Jason Y Tang,Igor F. Tsigelny,Jerry P. Greenberg,Mark A. Miller,Valentina L. Kouznetsova
{"title":"潜在的SARS-CoV-2非结构蛋白15抑制剂:重新利用fda批准的药物","authors":"Jason Y Tang,Igor F. Tsigelny,Jerry P. Greenberg,Mark A. Miller,Valentina L. Kouznetsova","doi":"10.14218/jerp.2021.00032","DOIUrl":null,"url":null,"abstract":"Severe acute respiratory syndrome coronavirus (SARS-CoV) 2 infection has caused millions of deaths worldwide, pushing the urgent need for an efficient treatment. Nonstructural protein 15 (NSP15) is a promising target due to its importance for SARS-CoV-2’s evasion of the host’s innate immune response.","PeriodicalId":73746,"journal":{"name":"Journal of exploratory research in pharmacology","volume":"18 4","pages":"000-000"},"PeriodicalIF":0.0000,"publicationDate":"2021-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Potential SARS-CoV-2 Nonstructural Protein 15 Inhibitors: Repurposing FDA-Approved Drugs\",\"authors\":\"Jason Y Tang,Igor F. Tsigelny,Jerry P. Greenberg,Mark A. Miller,Valentina L. Kouznetsova\",\"doi\":\"10.14218/jerp.2021.00032\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Severe acute respiratory syndrome coronavirus (SARS-CoV) 2 infection has caused millions of deaths worldwide, pushing the urgent need for an efficient treatment. Nonstructural protein 15 (NSP15) is a promising target due to its importance for SARS-CoV-2’s evasion of the host’s innate immune response.\",\"PeriodicalId\":73746,\"journal\":{\"name\":\"Journal of exploratory research in pharmacology\",\"volume\":\"18 4\",\"pages\":\"000-000\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-10-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of exploratory research in pharmacology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.14218/jerp.2021.00032\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of exploratory research in pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14218/jerp.2021.00032","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Potential SARS-CoV-2 Nonstructural Protein 15 Inhibitors: Repurposing FDA-Approved Drugs
Severe acute respiratory syndrome coronavirus (SARS-CoV) 2 infection has caused millions of deaths worldwide, pushing the urgent need for an efficient treatment. Nonstructural protein 15 (NSP15) is a promising target due to its importance for SARS-CoV-2’s evasion of the host’s innate immune response.